



Transaction Contacts

Coverage Team: Anurag Jindal, M.D. ECM Team:
Rahul Chaudhary
Patrick Morley



Leerink Partners Serves as Joint Bookrunner for Rocket Pharmaceuticals' (Nasdaq: RCKT) \$175 Million Follow-On Offering

Key Transaction Highlights

- Confidentially marketed deal that publicly launched after the close on September 12th, concurrently with the announcement of FDA alignment on Rocket's pivotal Phase 2 trial design for RP-A501 in Danon disease, and priced overnight.
- Well oversubscribed from both new and existing investors
- Base deal upsized from \$150 million at public launch to \$175 million
- Deal consisted of (i) 7,812,500 shares of common stock at an offering price of \$16.00 per share, and (ii) 3,126,955 pre-funded warrants to purchase common stock at an exercise price of \$15.99, representing a 4.6% premium to last sale
- Rocket Pharmaceuticals intends to use the net proceeds from this offering primarily to fund the further development of their pipeline of gene therapies for rare diseases, including the advancement of RP-A501 into a Phase 2 clinical trial and the continued clinical development of RP-A501, to accelerate the development of in-house manufacturing capabilities, and for general corporate purposes.
- This is Leerink Partners' 4th bookrun offering for Rocket and 40th bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click here.

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON 53 State Street 40th Floor Boston, MA 02109 CHARLOTTE 2151 Hawkins Street Suite 1025 Charlotte, NC 28203 NASHVILLE 40 Burton Hills Boulevard Suite 200 Nashville, TN 37215 NEW YORK 1301 Avenue of the Americas 12th Floor New York, NY 10019 SAN FRANCISCO 255 California Street 12th Floor San Francisco, CA 94111